Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients

What this Trial Is About

Researchers are comparing advanced immunochemotherapy treatments with classical immunochemotherapy in patients with relapsed or refractory high grade B cell lymphoma. The study aims to find out if advanced therapies like CAR-T therapy, bispecific antibodies, and antibody-drug conjugates provide better survival outcomes than classical treatments such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies. This observational study uses laboratory findings and electronic medical records to evaluate survival and treatment safety. Participants receive either advanced immunochemotherapy, including CAR-T therapy that modifies and expands their own T cells to target B cell antigens, bispecific antibodies which enhance immune activation without requiring cell modification, or antibody-drug conjugates that deliver targeted cytotoxic drugs to cancer cells. Alternatively, patients may receive classical immunochemotherapy treatments involving proteasome inhibitors, immune modulatory drugs, or monoclonal antibodies targeting specific cancer cell antigens. Treatments are not assigned by the study but observed as part of routine care. Throughout the study, researchers will monitor overall survival from the start of treatment or enrollment for up to 100 months, as well as progression-free survival. Data collection includes laboratory tests and review of medical records to assess outcomes and safety. Participation involves no intervention from the study team beyond data gathering, and the total observation period may extend up to several years to evaluate long-term effects.

Immunotherapy in Lymphoma